Protective role of p53 in doxorubicin-induced cardiomyopathy as a mitochondrial disease

Doxorubicin is widely used against cancer but carries the risk of a progressive cardiomyopathy associated with mitochondrial loss. Using genetic models, our recent study demonstrates that mitochondrial genomic DNA regulation by tumor protein p53 (TP53, best known as p53) prevents the cardiotoxicity...

Descripción completa

Detalles Bibliográficos
Autores principales: Nishi, Masahiro, Wang, Ping-Yuan, Hwang, Paul M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Author's Views
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7199752/
https://www.ncbi.nlm.nih.gov/pubmed/32391420
http://dx.doi.org/10.1080/23723556.2020.1724598
_version_ 1783529208227561472
author Nishi, Masahiro
Wang, Ping-Yuan
Hwang, Paul M.
author_facet Nishi, Masahiro
Wang, Ping-Yuan
Hwang, Paul M.
author_sort Nishi, Masahiro
collection PubMed
description Doxorubicin is widely used against cancer but carries the risk of a progressive cardiomyopathy associated with mitochondrial loss. Using genetic models, our recent study demonstrates that mitochondrial genomic DNA regulation by tumor protein p53 (TP53, best known as p53) prevents the cardiotoxicity of low dose doxorubicin which does not activate the p53-dependent cell death pathway.
format Online
Article
Text
id pubmed-7199752
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-71997522020-09-28 Protective role of p53 in doxorubicin-induced cardiomyopathy as a mitochondrial disease Nishi, Masahiro Wang, Ping-Yuan Hwang, Paul M. Mol Cell Oncol Author's Views Doxorubicin is widely used against cancer but carries the risk of a progressive cardiomyopathy associated with mitochondrial loss. Using genetic models, our recent study demonstrates that mitochondrial genomic DNA regulation by tumor protein p53 (TP53, best known as p53) prevents the cardiotoxicity of low dose doxorubicin which does not activate the p53-dependent cell death pathway. Taylor & Francis 2020-02-23 /pmc/articles/PMC7199752/ /pubmed/32391420 http://dx.doi.org/10.1080/23723556.2020.1724598 Text en © 2020 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
spellingShingle Author's Views
Nishi, Masahiro
Wang, Ping-Yuan
Hwang, Paul M.
Protective role of p53 in doxorubicin-induced cardiomyopathy as a mitochondrial disease
title Protective role of p53 in doxorubicin-induced cardiomyopathy as a mitochondrial disease
title_full Protective role of p53 in doxorubicin-induced cardiomyopathy as a mitochondrial disease
title_fullStr Protective role of p53 in doxorubicin-induced cardiomyopathy as a mitochondrial disease
title_full_unstemmed Protective role of p53 in doxorubicin-induced cardiomyopathy as a mitochondrial disease
title_short Protective role of p53 in doxorubicin-induced cardiomyopathy as a mitochondrial disease
title_sort protective role of p53 in doxorubicin-induced cardiomyopathy as a mitochondrial disease
topic Author's Views
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7199752/
https://www.ncbi.nlm.nih.gov/pubmed/32391420
http://dx.doi.org/10.1080/23723556.2020.1724598
work_keys_str_mv AT nishimasahiro protectiveroleofp53indoxorubicininducedcardiomyopathyasamitochondrialdisease
AT wangpingyuan protectiveroleofp53indoxorubicininducedcardiomyopathyasamitochondrialdisease
AT hwangpaulm protectiveroleofp53indoxorubicininducedcardiomyopathyasamitochondrialdisease

Ejemplares similares